DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fb328e/alpha6_beta4_integ) has announced the addition of the "Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2011" report to their offering.
The Alpha6 Beta4 Integrin signaling pathway activates the PI 3-kinase/Akt, MAPK/NFkB and SMAD signaling modules. There are today 210 companies plus partners developing 315 Alpha6Beta4 integrin pathway targeting drugs in 938 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 111 drugs.
This report lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 101 different targets. These targets are further categorized on in the software application by 29 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.
Find and sort drugs by twelve different parameters plus free text search field. Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser, whether it is a single drug profile or an entire search you want have a report of.
Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below. This Drug Pipeline Update contains 315 Alpha6Beta4 integrin pathway targeting drugs in development, which have a total of 938 developmental projects in cancer. In addition there are suspended and ceased drugs.
For more information, including an in-depth table of contents, visit http://www.researchandmarkets.com/research/fb328e/alpha6_beta4_integ
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines
For more information visit http://www.researchandmarkets.com/research/fb328e/alpha6_beta4_integ